Biomarkers
-
December 11, 2022
Taking Your Cancer Management to the Next Level: Webinar Recap
Sarah StanleyThere is no teacher quite like personal experience. Whether you are dealing with your own diagnosis or helping someone else, you become deeply familiar with cancer’s many practical and emotional challenges. Facing cancer can inspire people to help others navigate their own cancer journey. On November 9, 2022, Cancer Commons presented a free webinar featuring three passionate advocates who have drawn on their own… Read more »
- August 15, 2022
-
June 12, 2021
New Trial to Find Biomarkers to Guide Treatment Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.
.
-
September 18, 2018
Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes Bookmark
Emma Shtivelman, PhDExcerpt from OncLive:
“Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.
“In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”
Go to full article published by OncLive on Aug 29, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 22, 2018
Study Describes Design, Validation of Foundation Medicine’s Blood-Based TMB Test Bookmark
Emma Shtivelman, PhDExcerpt from GenomeWeb:
“Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation’s planned blood-based tumor mutational burden test.
“Appearing today in Nature Medicine, the study describes the development of the test and its characteristics, and its retrospective validation in two cohorts. Investigators demonstrated, by applying the assay to samples from two clinical trials, that blood-based TMB (bTMB) could reproducibly identify lung cancer patients who respond to immunotherapy treatment with Roche/Genentech’s atezolizumab (Tecentriq).”
Go to full article published by GenomeWeb on Aug 4, 2018 (Free registration required).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 21, 2018
Dana-Farber Researcher Sees Biomarker Potential in ESR1 Mutations Bookmark
Emma Shtivelman, PhDExcerpt from OncLive:
“As a medical oncologist and investigator, Rinath M. Jeselsohn, MD, focuses on the detection and clinical implications of ESR1 mutations in estrogen receptor–positive breast cancer. She is a member of the research team in the lab of Myles A. Brown, MD, at Dana-Farber Cancer Institute in Boston, Massachusetts, where investigators are seeking to elucidate the factors underlying the mechanisms of hormone responsiveness, particularly steroid hormone receptors, in human cancers.
“Jeselsohn, who has led numerous studies into ESR1 mutations, discussed the field in an interview with OncologyLive®.”
Go to full article published by OncLive on Aug 3, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.